Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics-Reference-Cited by-同舟云学术

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Published:2013-05-08 Issue:5 Volume:19 Page:698-705
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Kulkarni R.¹,Karim F. A.²,Glamocanin S.³,Janic D.⁴,Vdovin V.⁵,Ozelo M.⁶,Rageliene L.⁷,Carboni E.⁸,Laguna P.⁹,Dobaczewski G.¹⁰,Seremetis S.¹¹,Lindblom A.¹²,Santagostino E.¹³

Affiliation:

1. Department of Pediatrics and Human Development; Michigan State University; East Lansing; MI; USA

2. National Blood Centre; Kuala Lumpur; Malaysia

3. Hematology-Oncology Department; University Children's Hospital; Medical Faculty Skopje; Macedonia

4. Haematology/Oncology Department; University Children's Hospital; School of Medicine; University of Belgrade; Belgrade; Serbia

5. Hematological Center of Izmailovskaya Children Municipal Clinical Hospital; Moscow; Russian Federation

6. INCT do Sangue Hemocentro UNICAMP; University of Campinas; São Paulo; Brazil

7. Centre of Oncology and Hematology; Vilnius University Children's Hospital; Vilnius; Lithuania

8. Hospital Pequeno Principe; Curitiba; Brazil

9. Department of Paediatrics, Haematology and Oncology; Warsaw Medical University; Warsaw; Poland

10. Department of Pediatric BMT, Hematology and Oncology; Wrocław Medical University; Wrocław; Poland

11. Haemophilia R&D Portfolio; Novo Nordisk Inc.; Princeton; NJ; USA

12. Medical & Science Haemophilia; Novo Nordisk A/S; Soeborg; Denmark

13. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; IRCCS Cà Granda Foundation; Maggiore Hospital Policlinico; Milan; Italy

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12165/fullpdf

Reference17 articles.

1. Can haemophilic arthropathy be prevented?;Ljung;Br J Haematol,1998

2. Purification and characterization of a new recombinant factor VIII (N8);Thim;Haemophilia,2010

3. Development and introduction of recombinant factor VIII - a clinician's experience;Lusher;Haemophilia,2012

4. Inhibitors in young boys with haemophilia;Lusher;Baillieres Best Pract Res Clin Haematol,2000

5. Results from a large multinational clinical trial (guardian 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severre haemophilia A: safety and efficacy;Lentz;Haemophilia,2013

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study;Hematology;2024-02-20

2. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study;Transfusion;2023-10-18

3. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

4. Immunogenicity of Current and New Therapies for Hemophilia A;Pharmaceuticals;2022-07-23

5. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A;Haemophilia;2022-07-08